Clinical Practice Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus: 2024 Update.

Herein we present the update for the Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus. It involves the participation of several experts along the country, following the GRADE system. We included aspects regarding vaccines, pregnancy and cardiovascular risk which were not presented in the previous guidelines in 2017.
Competing Interests: Declaration of competing interest Deshire Alpizar-Rodriguez has undertaken previous work with GSK Mexico. Lilia Andrade-Ortega has been a speaker, or advisor, for Astra Zeneca and GSK. Sandra M. Carrillo-Vázquez has served as a lecturer for Abbvie, Asofarma, AstraZeneca, GSK, Novartis, and UCB. Sergio Durán-Barragán has been a speaker for Amgen, Janssen, Novartis, and Abbvie, as well as principal investigator in clinical trials with Lilly, Janssen, Novartis, Pfizer, Glaxo, Abbvie, Biogen, BMS, Astra Zeneca, Merck Serono, and UCB. Fedra Irazoque-Palazuelos has been a consultant and speaker for Abbvie, Lilly, and Janssen. Javier Merayo-Chalico has served as a speaker for Abbvie, Astra Zeneca, and Janssen. Sandra Sicsik-Ayala has been a speaker for Abbvie, Lilly, UCB, Janssen, and Roche. Luis H. Silveira has served as speaker for Johnson & Johnson, Teva, and Novartis. Daniel Xibillé-Friedmann has been a speaker and consultant for Astra Zeneca and Lilly, and conducted clinical trials with BMS and IDORSIA. The other authors have no conflict of interests to declare.
(Copyright © 2024 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.)